Physician profile
Alexander Clark
NPI 1578772109
$4,174.68
in general payments reported to CMS, 2019-2025
44 companies · $575 in 2025
The $575 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2020: $531 · 2021: $564 · 2022: $526 · 2023: $816 · 2024: $730 · 2025: $575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,122.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $646.15 | 2021-2025 | Vraylar |
| Gilead Sciences, INC. | $291.62 | 2019-2025 | |
| Novo Nordisk INC | $257.33 | 2019-2021 | |
| Lilly USA, LLC | $247.53 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.82 | 2019-2025 | Jardiance |
| Viiv Healthcare Company | $227.83 | 2022-2025 | Apretude |
| Pfizer INC. | $199.23 | 2019-2025 | |
| Glaxosmithkline, LLC. | $185.29 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Amarin Pharma, INC. | $160.50 | 2019-2021 | |
| Amgen INC. | $158.08 | 2019-2025 | Repatha, Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $157.09 | 2019-2025 | |
| Allergan, INC. | $155.23 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $119.55 | 2019-2025 | Airsupra |
| Astellas Pharma US INC | $84.22 | 2019-2025 | Veozah |
| Abbott Laboratories | $84.04 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.